ML213 5 mg | 99.74%
TargetMol
ML213 is a selective activator of Kv7.2 (KCNQ2) and Kv7.4 (KCNQ4) channels, enhances Kv7.2 and Kv7.4 channels with EC50s of 230 and 510 nM, respectively.
More Information Supplier PageML213
Search Results
Astragaloside II 5 mg | 99.70%
TargetMol
Astragaloside II is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
More Information Supplier PageAstragaloside II
Astragaloside II 10 mg | 99.70%
TargetMol
Astragaloside II is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
More Information Supplier PageAstragaloside II
Saikosaponin D 5 mg | 99.09%
TargetMol
Saikosaponin D is a novel SERCA inhibitor by inhibiting NF-κB and STAT3 signaling to protect against acetaminophen-induced hepatotoxicity.
More Information Supplier PageSaikosaponin D
Saikosaponin D 10 mg | 99.09%
TargetMol
Saikosaponin D is a novel SERCA inhibitor by inhibiting NF-κB and STAT3 signaling to protect against acetaminophen-induced hepatotoxicity.
More Information Supplier PageSaikosaponin D
Bay 59-3074 5 mg | 98.00%
TargetMol
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties.
More Information Supplier PageBay 59-3074
Bay 59-3074 50 mg | 98.00%
TargetMol
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties.
More Information Supplier PageBay 59-3074
Bay 59-3074 25 mg | 98.00%
TargetMol
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties.
More Information Supplier PageBay 59-3074
ICA-069673 100 mg | 99.66%
TargetMol
ICA-069673 is an activator of KCNQ2/Q3 potassium channel (IC50: 0.69 μM).
More Information Supplier PageICA-069673
ICA-069673 10 mg | 99.66%
TargetMol
ICA-069673 is an activator of KCNQ2/Q3 potassium channel (IC50: 0.69 μM).
More Information Supplier PageICA-069673